TRISALUS LF SC CM A (TLSI) competitors & alternatives
Health Care · NASDAQ
TRISALUS LF SC CM A (TLSI)'s top competitors and alternatives — its most similar public companies — include Boston Scientific (BSX), Medtronic (MDT), DELCATH SYS INC (DCTH), CG ONCOLOGY INC (CGON), BICARA THERAPEUTICS INC (BCAX), NOVOCURE LTD (NVCR), SELLAS LIFE SCIENCES GROUP INC (SLS), Cue Biopharma, Inc. (CUE), SAB BIOTHERAPEUTICS INC (SABS), LIFECORE BIOMEDICAL INC (LFCR), ACUMEN PHARMACEUTICALS INC (ABOS) and CONTEXT THERAPEUTICS INC (CNTX). These are TRISALUS LF SC CM A's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TLSI competitors & alternatives
-
Boston ScientificBSXHealth Care
Boston Scientific is a leading medical technology company delivering minimally invasive interventional solutions to improve patient health across diverse…
$42.97 (as of 2026-07-22) · market cap $63.7B
-
MedtronicMDTHealth Care
Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain,…
$81.89 (as of 2026-07-22) · market cap $105.1B
-
DELCATH SYS INCDCTHHealth Care
Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved…
$12.53 (as of 2026-07-22) · market cap $433M
-
CG ONCOLOGY INCCGONHealth Care
An early-stage immuno-oncology company developing cretostimogene, a novel therapeutic candidate for high-risk and intermediate-risk non-muscle-invasive bladder…
$69.31 (as of 2026-07-22) · market cap $6.3B
-
BICARA THERAPEUTICS INCBCAXHealth Care
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment…
$27.96 (as of 2026-07-22) · market cap $1.9B
-
NOVOCURE LTDNVCRHealth Care
Novocure delivers Tumor Treating Fields therapy through wearable medical devices to treat aggressive cancers including glioblastoma, lung cancer, and…
$15.57 (as of 2026-07-22) · market cap $1.8B
-
SELLAS LIFE SCIENCES GROUP INCSLSHealth Care
SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid…
$12.08 (as of 2026-07-22) · market cap $2.2B
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
SAB BIOTHERAPEUTICS INCSABSHealth Care
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1…
$3.58 (as of 2026-07-22) · market cap $278M
-
LIFECORE BIOMEDICAL INCLFCRHealth Care
Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry.
$4.58 (as of 2026-07-22) · market cap $174M
-
ACUMEN PHARMACEUTICALS INCABOSHealth Care
Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients,…
$2.21 (as of 2026-07-22) · market cap $160M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
Not quite? Describe exactly what you want →
Peers are TRISALUS LF SC CM A's closest public companies by shared sub-industry, sector and business themes. See the full profile: TRISALUS LF SC CM A (TLSI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.